2022 The primal essence of targeted drug delivery: Can it deliver enough drug to cure? (NIH TDIG)
2019 Couvreur and Park, Stars collide debate: Big-vs. Nano-progress (CRS)
2015 Park, 30 Years of Research on Drug Delivery: A Personal Reflection
- 2011 Bae, Targeted Drug Delivery to Tumors- Myths, Reality, and Possibility.pdf
- 2012 Kwon, Analysis on the current status of targeted drug delivery to tumors.pdf
- 2013 Park, Facing the truth about nanotechnology in drug delivery.pdf
- 2013 Park, Questions on the role of the EPR effect in tumor targeting.pdf
- 2014 Park, Controlled drug delivery systems- Past forward and future back.pdf
- 2014 Park, Translation from mouse to human- Time to think in new boxes.pdf
- 2014 Yun, Controlled drug delivery systems- The next 30 years.pdf
- 2015 Lee, Smart nanoparticles for drug delivery- Boundaries and opportunities.pdf
- 2015 Yun, Controlled Drug Delivery- Historical perspective for the next generation.pdf
- 2016 Park, Drug Delivery of the Future- Chasing the Invisible Gorilla.pdf
- 2016 Park, Drug delivery research- The invention cycle.pdf
- 2016 Paterson, Challenges, opportunities, and the future of physiological publications in the hype cycle.pdf
- 2017 Mitragotri, Drug delivery research for the future- Expanding the nano horizons and beyond.pdf
- 2017 Park, The drug delivery field at the inflection point- Time to fight its way out of the egg.pdf
- 2017 Park, The drug delivery field needs a well-diversified technology portfolio.pdf
- 2018 Florence, Nanotechnologies for site specific drug delivery- Changing the narrative.pdf
- 2018 Leroux, The novelty bubble.pdf
- 2018 Reineke, Terminology matters- There is no targeting, but retention.pdf
- 2018 Witzigmann, Translating nanomedicines_ Thinking beyond materials A young investigator's reply to ‘The Novelty Bubble’.pdf
- 2018 Youn, Perspectives on the past, present, and future of cancer nanomedicine.pdf
- 2019 298 Park, Transcending nanomedicine to the next level- Are we there yet.pdf
- 2019 300 Park, Collective progress in drug delivery.pdf
- 2019 302 Park, What do we do next.pdf
- 2019 305 Park, The beginning of the end of the nanomedicine hype.pdf
- 2019 307 Park, Fresh Air in the JCR Editorial Team.pdf
- 2019 308 Park, Science the endless frontier.pdf
- 2019 309 Grodzinski, NCI Centers of Cancer Nanotechnology Excellence (CCNEs)- A full story to set the record straight.pdf
- 2020 Erden, The long life of unicorns.pdf
- 2020 Moghimi, Tuning the Engines of Nanomedicine.pdf
- 2020 Park, JCR is attuned for the 2020s.pdf
- 2021 Florence, Trajectories in nanotechnology- embracing complexity, seeking analogies.pdf
- 2021 Park, Are controlled release scientists doing enough for our environmen.pdf
- 2021 Sullivan, We should ditch awards in science.pdf
- 2021 Taylor, Celebrating women in the pharmaceutical sciences.pdf
- 2021 Wu, Nanoparticle-mediated cytoplasmic delivery of messenger RNA vaccines.pdf
- 2022 Dirnagl, Reproducibility, relevance and reliability as barriers to efficient and credible biomedical technology translation.pdf
- 2022 Moghimi, Use of 'nano' prefix is no small matter.pdf
- 2022 Park, Evolution of drug delivery systems- From 1950 to 2020 and beyond.pdf
- 2022 Park, Perspective on drug delivery in 2050.pdf
- 2022 Park, The primal essence of targeted drug delivery- Can it deliver enough drug to cure (NIH TDIG).pdf
- 2022 Taylor, Faking it: Impostor syndrome in the pharmaceutical sciences.pdf
- 2022 Taylor, The myth of meritocracy in the pharmaceutical sciences.pdf
- 2022 Yang, Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.pdf
- 2023 Florence, Professor Ian G. Tucker- Man of many talents.pdf
- 2023 Park, It's not the animal model, inadequate. It's the human use, inadequate (NCI).pdf
